Cargando…

Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach

BACKGROUND: Transition from pediatric to adult care of patients affected by Inflammatory Bowel Disease (IBD) is a critical step that needs specific care and multidisciplinary involvement. The aim of our study was to evaluate the outcome of the transition process of a cohort of IBD patients, explorin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corsello, Antonio, Pugliese, Daniela, Bracci, Fiammetta, Knafelz, Daniela, Papadatou, Bronislava, Aloi, Marina, Cucchiara, Salvatore, Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844940/ https://www.ncbi.nlm.nih.gov/pubmed/33509223 http://dx.doi.org/10.1186/s13052-021-00977-x

Ejemplares similares

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Diet and Nutrients in Gastrointestinal Chronic Diseases
por: Corsello, Antonio, et al.
Publicado: (2020)

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy
por: Pietropaolo, Giuseppe, et al.
Publicado: (2020)

Orphan patients with inflammatory bowel disease - when we treat beyond evidence
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Challenges in paediatric inflammatory bowel diseases in the COVID-19 time
por: Dipasquale, Valeria, et al.
Publicado: (2020)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Frontiers in Drug Research and Development for Inflammatory Bowel Disease
por: Currò, Diego, et al.
Publicado: (2017)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
por: Scaldaferri, Franco, et al.
Publicado: (2020)

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
por: Alvisi, Patrizia, et al.
Publicado: (2019)

Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
por: Alivernini, Stefano, et al.
Publicado: (2018)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies
por: Armuzzi, Alessandro, et al.
Publicado: (2019)

The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable”
por: Pugliese, Daniela, et al.
Publicado: (2020)

Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022)

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2018)

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study
por: Pugliese, Daniela, et al.
Publicado: (2018)

Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial
por: Di Nardo, Giovanni, et al.
Publicado: (2013)

Mucosal healing in ulcerative colitis: surveillance or colectomy?
por: Andrisani, Gianluca, et al.
Publicado: (2013)

Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis
por: Pierdomenico, Maria, et al.
Publicado: (2018)

Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice
por: Vitali, Roberta, et al.
Publicado: (2013)

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
por: Papa, Alfredo, et al.
Publicado: (2022)

Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies
por: Pugliese, Daniela, et al.
Publicado: (2022)

Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD)
por: Erős, Adrienn, et al.
Publicado: (2020)

Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease
por: Di Domenicantonio, Riccardo, et al.
Publicado: (2018)

Novel Topics in Inflammatory Bowel Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2016)

Fecal Microbiota Transplantation in Inflammatory Bowel Disease: Beyond the Excitement
por: Ianiro, Gianluca, et al.
Publicado: (2014)

Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery
por: Papa, Alfredo, et al.
Publicado: (2020)

Circular and Circulating DNA in Inflammatory Bowel Disease: From Pathogenesis to Potential Molecular Therapies
por: Di Vincenzo, Federica, et al.
Publicado: (2023)

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase
por: Papa, Alfredo, et al.
Publicado: (2020)

Incident Colorectal Cancer in Inflammatory Bowel Disease
por: Neri, Benedetto, et al.
Publicado: (2022)

A rare case of epiploic appendagitis in a patient affected by ulcerative colitis on vedolizumab therapy
por: Pugliese, Daniela, et al.
Publicado: (2022)

Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Splenomegaly as a Primary Manifestation of Gaucher Disease in a Young Adult Woman
por: Merra, Giuseppe, et al.
Publicado: (2008)

Tumorigenesis in Inflammatory Bowel Disease: Microbiota-Environment Interconnections
por: Mignini, Irene, et al.
Publicado: (2023)

Irritable Bowel Syndrome (IBS) and Non-Celiac Gluten Sensitivity (NCGS): Where Is the Culprit Hiding? Nutritional Tips for Gastroenterologists
por: Rinninella, Emanuele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5gg5nvg1rfg7cvomrnr19uoosm